Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients With Resected Adenocarcinoma of the Pancreas

NCT02261714 is registered in ClinicalTrials.gov with Targovax ASA as lead sponsor.

NCT NCT02261714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02261714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients With Resected Adenocarcinoma of the Pancreas
Lead sponsor
Targovax ASA
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2012
Completion date
May 31, 2019
Enrollment
32 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, resected